Of course.
The question won't be answered in it's entirety until the CLIA waiver is done.
Currently the market is confined to those who have CLIA trained staff - and they mostly have their own lab, thereby making FebriDx unwanted.
Once GP Surgeries, Pharmacists, rural 'cottage' Hospitals can use it via the clia waiver then the whole picture becomes clear.
Honestly, IMHO, the SP fall isn't because the product sales were terrible (which of course they were) but because management lied out of their backsides about 'robust' sales.
Add that to the debacle around the Covid test, and the market walked away with a feeling of Deja Vu.
Management caused this, not bad sales figures.
Add to My Watchlist
What is My Watchlist?
